Literature DB >> 24416568

Interleukin-6 (IL-6) and C-reactive protein (CRP) concentration prior to total nephrectomy are prognostic factors in localized renal cell carcinoma (RCC).

Michał Hrab1, Karolina Olek-Hrab2, Andrzej Antczak1, Zbigniew Kwias1, Tomasz Milecki3.   

Abstract

BACKGROUND: Radical nephrectomy is the gold standard for treatment of renal cell carcinoma (RCC), but even for localized disease the survival rates are still unsatisfactory. Identification of prognostic factorsl is the basis for future treatment strategies for an individual patient. AIM: The aim of our study was to assess the usefulness of the concentration of IL-6 and CRP as prognostic factors in patients after nephrectomy due to localized RCC.
MATERIALS AND METHODS: Our prospective study included 89 patients (55 men and 34 women) who had been surgically treated for RCC. The examined group included patients with localized advanced disease (from T1 to T3) with no metastases in lymph nodes (N0), and with no distant metastases (M0). All patients had blood samples drawn three times during the study (one day before surgery, six days after surgery and 6 months after surgery) to evaluate the concentration of CRP and IL-6. In each patient RCC of the kidney was removed during radical nephrectomy. Statistical analysis was conducted using statistica v.7.0.
RESULTS: Statistically significant relationships were found between the concentration of CRP before the operation and OS (p = 0.0001). CRP concentration at baseline was statistically significantly correlated with CSS (p = 0.0004). The level of IL-6 assessed before the surgery was significantly correlated with survival times such as OS (p = 0.0096) and CSS (p = 0.0002). The concentration of IL-6 and CRP measured 6 days after surgery and 6 months after surgery were not statistically significantly correlated with survival times.
CONCLUSIONS: Results of our study showed that elevated levels of IL-6 and CRP in peripheral blood before surgery of RCC were correlated with worse OS and CSS.

Entities:  

Keywords:  C-reactive protein; Interleukin-6; Nephrectomy; Prognostic factors; Renal cell carcinoma

Year:  2013        PMID: 24416568      PMCID: PMC3863166          DOI: 10.1016/j.rpor.2013.06.002

Source DB:  PubMed          Journal:  Rep Pract Oncol Radiother        ISSN: 1507-1367


  29 in total

1.  Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma.

Authors:  T Nozoe; H Saeki; K Sugimachi
Journal:  Am J Surg       Date:  2001-08       Impact factor: 2.565

2.  Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma.

Authors:  Yoshinobu Komai; Kazutaka Saito; Kunihiko Sakai; Shinji Morimoto
Journal:  BJU Int       Date:  2006-09-06       Impact factor: 5.588

Review 3.  Prognostic markers in renal cell carcinoma.

Authors:  Börje Ljungberg
Journal:  Curr Opin Urol       Date:  2007-09       Impact factor: 2.309

4.  Absolute preoperative C-reactive protein predicts metastasis and mortality in the first year following potentially curative nephrectomy for clear cell renal cell carcinoma.

Authors:  T V Johnson; A Abbasi; A Owen-Smith; Andrew Young; K Ogan; J Pattaras; P Nieh; F F Marshall; V A Master
Journal:  J Urol       Date:  2009-12-14       Impact factor: 7.450

5.  [Serum levels and gene expressions of interleukin-1 beta (IL-1 beta), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) in human renal cell carcinomas].

Authors:  T Hamao; H Kanayama; M Kan; H Takigawa; S Kagawa
Journal:  Nihon Hinyokika Gakkai Zasshi       Date:  1994-04

6.  Prognostic role of c-met expression in breast cancer patients.

Authors:  Iwona Gisterek; Ewelina Lata; Agnieszka Halon; Rafal Matkowski; Jolanta Szelachowska; Przemyslaw Biecek; Jan Kornafel
Journal:  Rep Pract Oncol Radiother       Date:  2011-06-08

7.  Nasopharyngeal carcinoma in Slovenia, 1990-2003 (results of treatment with conventional two-dimensional radiotherapy).

Authors:  Janka Carman; Primož Strojan
Journal:  Rep Pract Oncol Radiother       Date:  2012-03-06

8.  [Assessment of changes in levels of interleukin 6 and C reactive protein in patients with breast tumors].

Authors:  Irena Zakrzewska; Leszek Kozłowski; Marek Wojtukiewicz
Journal:  Pol Merkur Lekarski       Date:  2003-08

9.  [Significance of plasma interleukin-6 in the diagnosis of renal cell carcinoma].

Authors:  H Kamemoto
Journal:  Hinyokika Kiyo       Date:  1993-04

10.  The relationship between the preoperative systemic inflammatory response and cancer-specific survival in patients undergoing potentially curative resection for renal clear cell cancer.

Authors:  G W A Lamb; D C McMillan; S Ramsey; M Aitchison
Journal:  Br J Cancer       Date:  2006-03-27       Impact factor: 7.640

View more
  12 in total

1.  Re: Impact of preoperative hemoglobin and CRP levels on cancer-specific survival in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder: results of a single-center study.

Authors:  Ozgu Aydogdu; Ibrahim Halil Bozkurt; Tarik Yonguc
Journal:  World J Urol       Date:  2016-07-27       Impact factor: 4.226

2.  IL-37 mediates the antitumor activity in renal cell carcinoma.

Authors:  Yazhuo Jiang; Yili Wang; Liang Liang; Yang Gao; Juan Chen; Yi Sun; Yongyi Cheng; Yonggang Xu
Journal:  Med Oncol       Date:  2015-10-13       Impact factor: 3.064

3.  Impact of preoperative hemoglobin and CRP levels on cancer-specific survival in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder: results of a single-center study.

Authors:  T Grimm; A Buchner; B Schneevoigt; A Kretschmer; M Apfelbeck; M Grabbert; J F Jokisch; C G Stief; A Karl
Journal:  World J Urol       Date:  2015-09-16       Impact factor: 4.226

4.  Prognostic role of interleukin-6 in renal cell carcinoma: a meta-analysis.

Authors:  Y Wang; Y Zhang
Journal:  Clin Transl Oncol       Date:  2019-08-13       Impact factor: 3.405

5.  IL-6 is involved in malignancy and doxorubicin sensitivity of renal carcinoma cells.

Authors:  Yanqiang Chen; Jianzhen Liu; Pei Lv; Jiangyan Gao; Mingzheng Wang; Yongjun Wang
Journal:  Cell Adh Migr       Date:  2017-06-19       Impact factor: 3.405

6.  Association of Expression Levels or Activation Status of STAT3 with Treatment Outcomes of Sunitinib in Patients with Renal Cell Carcinoma.

Authors:  Kazuhiro Yamamoto; Takuto Hara; Tsutomu Nakagawa; Midori Hirai; Hideaki Miyake; Masato Fujisawa; Ikuko Yano
Journal:  Target Oncol       Date:  2018-06       Impact factor: 4.493

7.  The role of CRP and ATG9B expression in clear cell renal cell carcinoma.

Authors:  Zheng Ma; Zengguang Qi; Zhengfei Shan; Jiangsong Li; Jing Yang; Zhonghua Xu
Journal:  Biosci Rep       Date:  2017-11-15       Impact factor: 3.840

8.  Critical evaluation of the potential prognostic value of the pretreatment-derived neutrophil-lymphocyte ratio under consideration of C-reactive protein levels in clear cell renal cell carcinoma.

Authors:  Orietta Dalpiaz; Theresa Luef; Maximilian Seles; Michael Stotz; Tatjana Stojakovic; Karl Pummer; Richard Zigeuner; Georg C Hutterer; Martin Pichler
Journal:  Br J Cancer       Date:  2016-12-01       Impact factor: 7.640

9.  Tumour cell expression of interleukin 6 receptor α is associated with response rates in patients treated with sunitinib for metastatic clear cell renal cell carcinoma.

Authors:  Martin Pilskog; Leif Bostad; Reidunn J Edelmann; Lars A Akslen; Christian Beisland; Oddbjørn Straume
Journal:  J Pathol Clin Res       Date:  2018-03-05

10.  Prognostic value of interleukin-6 and interleukin-6 receptor in organ-confined clear-cell renal cell carcinoma: a 5-year conditional cancer-specific survival analysis.

Authors:  Qiang Fu; Yuan Chang; Huimin An; Hangcheng Fu; Yu Zhu; Le Xu; Weijuan Zhang; Jiejie Xu
Journal:  Br J Cancer       Date:  2015-11-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.